Objective:To systematically evaluate the efficacy and safety of Hugan Tablets(护肝片)in the treatment of drug-induced liver injury.Methods:Totally seven Chinese and English databases,including CNKI,Wanfang,VIP,CBM,Pub...Objective:To systematically evaluate the efficacy and safety of Hugan Tablets(护肝片)in the treatment of drug-induced liver injury.Methods:Totally seven Chinese and English databases,including CNKI,Wanfang,VIP,CBM,PubMed,EMbase,Web of Science were searched for randomized controlled trials(RCTs)of Hugan Tablets(护肝片)for the treatment of drug-induced liver injury,which were published from the date of establishment to April 20,2019.The meta-analysis software RevMan 5.3 software and Excel were used to build a database into combine and analyze the studies that met the standards and to draw a forest plot.Results:Forty five RCTs were included with 7478 patients.The quality of included studies was uneven.Meta-analysis showed that the outcome index of liver injury rate was divided into seven subgroups.Hugan Tablets(护肝片)were used in the treatment of anti-tuberculosis drugs was superior to the conventional western medicine treatment group(RR=0.27,95%CI[0.22,0.33],P<0.00001).Which was also better than the without Hugan Tablets(护肝片)treatment group(RR=0.32,95%CI[0.20,0.52],P<0.00001).For the role of drug-induced liver injury in the treatment of type 2 diabetes,the Hugan Tablet+conventional treatment group is better than the conventional treatment group(RR=0.16,95%CI[0.03,0.88],P=0.03).The effect of drug-induced liver injury in the treatment of hypertension was superior to the conventional western medicine treatment group(RR=0.07,95%CI[0.03,0.14],P<0.00001).The effect of drug-induced liver injury during the treatment of hyperlipidemia was not statistically significant(RR=0.57,95%CI[0.33,1.00],P=0.05).There was no statistical difference between the two groups in the effect of drug-induced liver injury during the treatment of coronary heart disease(RR=0.09,95%CI[0.01,1.61],P=0.10).There was no significant difference between the two groups in the treatment of cerebral thrombosis for drug-induced liver injury(RR=0.11,95%CI[0.01,2.01],P=0.14).The effect of anti-hyperthyroidism on liver injury was better than that of conventional western medicine treatment group(RR=0.45,95%CI[0.25,0.82],P=0.009).Outcome index of total effective rate was divided into two subgroups.The effect of drug-induced liver injury caused by the type of drug was not mentioned was superior to the conventional western medicine treatment group(RR=0.78,95%CI[0.70,0.88],P<0.0001).There was no significant difference between the two groups in the liver injury caused by antipsychotic drugs(RR=0.97,95%CI[0.81,1.16],P=0.72).Conclusion:When used in the treatment of tuberculosis and psychiatric drug treatment,combineduse of Hugan Tablets(护肝片)can significantly reduce the incidence of drug-induced liver damage,and can significantly improve clinical symptoms caused by liver damage.In the treatment of hypertension,the addition of Hugan Tablets(护肝片)can significantly reduce the incidence of drug-induced liver injury,improving the safety of medication.In the treatment of drug-induced liver injury caused by which drug is not mentioned,Hugan Tablet has a therapeutic effect.Slight adverse reactions were reported,including rash,headache,palpitations,hypoglycemia,flushing,fatigue,nausea,bowel sounds,flatulence,diarrhea,and gastrointestinal discomfort.All studies reported minor adverse reactions that were well tolerated by patients and recovered without treatment after discontinuation.Oral administration of Hugan Tablets(护肝片)has positive effects on druginduced liver injury,but this conclusion still needs further evidences delete.It is necessary to adopt a larger sample,more design,and accord with the international standards to improve the quality of evidence.展开更多
To evaluate the effectiveness and safety of Jinye Baidu Granules(金叶败毒颗粒)for acute upper respiratory tract infection(AURTI).Database such as CNKI,Wan-fang,VIP,Sino Med,Web of science,Clinical Trials gov,Medline、...To evaluate the effectiveness and safety of Jinye Baidu Granules(金叶败毒颗粒)for acute upper respiratory tract infection(AURTI).Database such as CNKI,Wan-fang,VIP,Sino Med,Web of science,Clinical Trials gov,Medline、EMBASE,CENTRAL,Cochrane Library were retrieved to collect randomized controlled trials(RCTs)on Jinye Baidu Granules(金叶败毒颗粒)in treating AURTI from the estabslishment of the database to March 2019.A total of 2 reviewers independently screened the literature according to the inclusion and exclusion criteria,and extracted material and the quality evaluation of the included studies.Quality evaluation adopted Cochrane Handbook 5.1 evaluation standards and tools.Rev Man5.3 was used to perform Meta-analysis for the adopted study.Finally a total of 4 RCTs involving 636 patients were included.Meta-analysis results showed that:compared with conventional Western medicine alone,Jinye Baidu Granules(金叶败毒颗粒)combined with Western medicine in the treatment of acute upper respiratory tract infection can improve the total effective rate of clinical efficacy[RR=0.13,95%CI(0.06,0.29),P<0.00001],shorten the time of antipyretic time for acute upper respiratory tract infection[MD=–1.22,95%CI(–1.43,–1.00),P<0.00001],shorten the time of pharyngeal pain[MD=–1.97,95%CI(–2.97,–0.96),P<0.0001]and shorten the cough disappear time[MD=–1.97,95%CI(–2.97,–0.96),P<0.0001].There were 2 papers reporting adverse reactions during the study period,and one of them specifically reported diarrhea,nausea,vomiting and stomachache in the experimental group.In the control group:diarrhea,nausea and adverse reactions disappeared after drug withdrawal;the incidence of adverse reactions was 3.92%in the control group and 5.88%in the observation group.There was no significant difference between the 2 groups(P>0.05).Based on existing data and methods,the systematic evaluation showed that,compared with Western medicine alone,Jinye Baidu Granules(金叶败毒颗粒)combined with Western medicine alone could improve the total effective rate of clinical efficacy,reduce the time of fever,sore throat,and the disappearance of cough with less adverse reactions.However,due to the low quality of the included study,large samples,multicenter,randomized,double-blind trials and trials are still needed to randomized controlled trials with reference to the CONSORT standard and the STRICTA statement.展开更多
To systematically evaluate the efficacy and safety of Pudilan Xiaoyan Oral in Liquid(蒲地蓝消炎口服液)in the treatment of suppurative tonsillitis in children.In WanFang,CNKI,VIP,CBM,PubMed,Embase and Corchrane and oth...To systematically evaluate the efficacy and safety of Pudilan Xiaoyan Oral in Liquid(蒲地蓝消炎口服液)in the treatment of suppurative tonsillitis in children.In WanFang,CNKI,VIP,CBM,PubMed,Embase and Corchrane and other databases,relevant literatures about Pudilan Xiaoyan Oral Liquid(蒲地蓝消炎口服液)in the treatment of pediatric suppurative tonsillitis were searched.The retrieval time was from the establishment of the database to April 2019.Relevant randomized controlled trials were extracted.The control group was treated with conventional antibiotics,and the observation group was treated with Pudilan Xiaoyan Oral Liquid(蒲地蓝消炎口服液)based on the control group.After they were summarized and analyzed,Cochrane Handbook 5.1 evaluation standard and RevMan 5.3 software were used to determine the quality of literature.A total of 172 literatures were retrieved and 23 randomized controlled trials were included.A total of 1188 children were in the experimental group while 1175 children were in the control group,involving 2363 children with suppurative tonsillitis.Meta-analysis showed that the total effective rate of Pudilan Xiaoyan Oral Liquid(蒲地蓝消炎口服液)combined with routine treatment was better than that of routine treatment(RR=0.88,95%CI(0.86,0.91),P<0.00001);Pudilan Xiaoyan Oral Liquid(蒲地蓝消炎口服液)combined with routine treatment in children was better than that of routine treatment alone in term of temperature recovery,sore throat time,the reduction of tonsil purulent secretion.There were few reports of adverse reactions and no serious adverse reactions.To sum up,Pudilan Xiaoyan Oral Liquid(蒲地蓝消炎口服液)combined with routine treatment can significantly improve the efficacy of children with suppurative tonsillitis,but due to the low quality of the included literature,it should be used cautiously.It is suggested that clinical randomized controlled trials should be designed with large sample size,multi-centers and conforming to international standards to improve the quality of evidence.展开更多
Objective:To systematically evaluate the efficacy and safety of Fuke Qianjin Tablets(妇科千金片)in the treatment of chronic pelvic inflammation.Methods:A systematically and comprehensively search was conducted in 4 Ch...Objective:To systematically evaluate the efficacy and safety of Fuke Qianjin Tablets(妇科千金片)in the treatment of chronic pelvic inflammation.Methods:A systematically and comprehensively search was conducted in 4 Chinese databases of CNKI,VIP,Wan Fang and CBM and the foreign language databases of Pubmed,EMbase and The Cochrane Library.The retrieval time was from database establishment to March 2019.The randomized controlled trials of Fuke Qianjin Tablets(妇科千金片)in the treatment of chronic pelvic inflammation were selected according to the predetermined criteria.The quality of the included study was evaluated by Cochrane collaborative network bias risk evaluation tool,and the meta-analysis was performed by Rev Man5.3 software.Results:A total of 1009 related literatures were searched.After initial screening and strict evaluation,55 studies were included,with a total sample size of 6826 cases,including 3416 cases in the experiment group and 3410 cases in the control group.The results of meta-analysis showed that the total effective rate of Fuke Qianjin Tablets(妇科千金片)combined with antibiotics in the treatment of chronic pelvic inflammation was better than that of antibiotics alone(RR=1.20,95%CI[1.17,1.22],P<0.00001).Fuke Qianjin Tablets(妇科千金片)combined with antibiotics was better than that of antibiotics alone in the improvement of abdominal pain symptoms(RR=1.40,95%CI[1.04,1.88],P<0.00001),leukorrhea abnormality(RR=1.38,95%CI[1.16,1.65],P<0.0004).In terms of safety,Fuke Qianjin Tablets(妇科千金片)combined with antibiotics could reduce the incidence of adverse reactions(RR=0.67,95%CI[0.48,0.93],P<0.02).The main adverse reactions were nausea and vomiting,bitterness and astringency in the mouth,rash and so on.All of them could be tolerated and the symptoms could disappear in the short term,and had no effect on the treatment.Conclusion:Fuke Qianjin Tablets(妇科千金片)combined with antibiotics in the treatment of chronic pelvic inflammation can improve the total effective rate,relieve abdominal pain and abnormal leukorrhea and other clinical discomfort symptoms,improve the quality of life of patients to a certain extent,and no serious adverse reactions are found.Due to the limitation of the quality and quantity of the included literature,the above conclusions need to be further studied and verified by high-quality research.展开更多
Objective:To explore the efficacy of Lianhua Qingwen Capsule(莲花清瘟胶囊)on upper respiratory tract infection,to understand the impact of Lianhua Qingwen Capsule(莲花清瘟胶囊)on the treatment outcome of upper respira...Objective:To explore the efficacy of Lianhua Qingwen Capsule(莲花清瘟胶囊)on upper respiratory tract infection,to understand the impact of Lianhua Qingwen Capsule(莲花清瘟胶囊)on the treatment outcome of upper respiratory tract infection,and provide reference for rational clinical drug use.Methods:The HIS database based on 18 large third-grade class-A hospitals was selected to match 1:1 for upper respiratory tract infection patients using and without Lianhua Qingwen Capsule(莲花清瘟胶囊)according to certain standards.The recombination of treatment outcome as"recovery"and"improvement"in the database was defined as effective treatment,"ineffectiveness","death"and"other"as ineffectivetreatment populations,and the effectiveness of treatment outcomes in the remerged 2 groups was compared by propensity score method.Results:After matching,454 cases were in both the patients treated by(experimental group)and without(control group)Lianhua Qingwen Capsule(莲花清瘟胶囊).Analysis was performed by three Logistic regression methods,all showing regression coefficients greater than 0 and statistically significant differences(P<0.05).Conclusion:Patients with upper respiratory tract infection treated by Lianhua Qingwen Capsule(莲花清瘟胶囊)are more effective than that without Lianhua Qingwen Capsule(莲花清瘟胶囊),it can improve the clinical efficacy of patients with upper respiratory tract infection。展开更多
To systematically evaluate the clinical efficacy and safety of Maren Runchang Pill(麻仁润肠丸)in the treatment of senile constipation.Randomized controlled trials(RCT)on the treatment of senile constipation with Maren...To systematically evaluate the clinical efficacy and safety of Maren Runchang Pill(麻仁润肠丸)in the treatment of senile constipation.Randomized controlled trials(RCT)on the treatment of senile constipation with Maren Runchang Pill(麻仁润肠丸)were searched by computer in CNKI,CBM,WanFang,VIP,PubMed,EMbase and the Cochrane Library databases.The retrieval time limit was from the establishment of the database to May 2019.A total of 2 researchers independently screened literature and extracted data according to the inclusion criteria,and Meta-analyzed the RCT that met the standards by applying RevMan5.3 software.A total of 5 randomized controlled trials were included,including 395 patients with senile constipation,199 in the experimental group and 196 in the control group.The treatment group was treated with Maren Runchang Pill(麻仁润肠丸),while the control group was treated with other Western medicine,including fruit guide tablets,lactulose oral liquid or kaisailu,etc.The results of Meta-analysis showed that there was no significant difference in the total clinical efficacy between Maren Runchang Pill(麻仁润肠丸)and other Western medicines[RR=1.02,95%CI(0.88,1.17),P=0.83].In terms of improvement of abdominal distension and inappetence,there was no significant difference between the treatment with Maren Runchang Pill(麻仁润肠丸)and other Western medicine[RR=1.03,95%CI(0.85,1.24),P=0.78].Maren Runchang Pill(麻仁润肠丸).This study showed that the efficacy of Maren Runchang Pill(麻仁润肠丸)in the treatment of senile constipation was not significantly different from that of conventional Western medicine,and was safe,and effective,with few adverse reactions.Maren Runchang Pill(麻仁润肠丸),as a traditional Chinese patent medicine,can play the role of regulating qi and replenishing blood,and regulating bowel and bowel laxative,with fewer cost.It is more suitable for the elderly to use,with good compliance,and clinically it should be used with syndrome differentiation.However,due to the quantity and quality of the original study,multi-center,high-quality randomized controlled trials are still needed to further confirm it.展开更多
系统评价热毒宁注射液治疗急性气管-支气管炎的有效性和安全性。计算机检索中国知网、万方、维普、Sino Med、Cochrane Library、Medline、Web of Science从建库至2019年4月发表的期刊文献、学术论文及会议论文,收集热毒宁注射液治疗急...系统评价热毒宁注射液治疗急性气管-支气管炎的有效性和安全性。计算机检索中国知网、万方、维普、Sino Med、Cochrane Library、Medline、Web of Science从建库至2019年4月发表的期刊文献、学术论文及会议论文,收集热毒宁注射液治疗急性气管-支气管炎的随机对照试验(RCTs)。由2名研究者独立进行文献筛选、数据提取及偏倚风险评估,采用Rev Man 5.3进行Meta分析。最终纳入14篇随机对照试验文献,涉及1652例患者。Meta分析结果显示:在临床总有效率方面,热毒宁注射液优于利巴韦林治疗(RR=1.37,95%CI[1.28,1.47],P<0.00001);热毒宁注射液联合常规治疗优于常规治疗(RR=1.14,95%CI[1.09,1.19],P<0.00001);热毒宁注射液联合阿奇霉素治疗优于阿奇霉素治疗(RR=1.21,95%CI[1.07,1.37],P=0.002)。在临床症状方面,热毒宁注射液治疗的平均退热时间短于利巴韦林治疗(MD=-1.68,95%CI[-1.72,-1.49],P<0.00001);咳嗽消失时间短于利巴韦林治疗(MD=-2.57,95%CI[-2.91,-2.24],P<0.00001);肺部啰音消失时间短于利巴韦林治疗(MD=-2.26,95%CI[-2.71,-1.80],P<0.00001);热毒宁注射液联合常规治疗肺部啰音消失时间短于单用常规治疗(MD=-1.77,95%CI[-1.95,-1.59],P<0.00001)。基于此研究结果,热毒宁注射液治疗可提高临床总有效率,缩短平均退热时间、咳嗽与肺部啰音消失时间,不良反应轻微且发生率低。但鉴于纳入研究质量不高,需采用大样本、设计严谨、符合国际规范的临床试验方案以提高证据质量级别。展开更多
基金National Key Research and Development Program of China(2018YFC1707400)Research Project of Graduate Education and Teaching Reform of China Academy of Chinese Medical Sciences(JG201703)
文摘Objective:To systematically evaluate the efficacy and safety of Hugan Tablets(护肝片)in the treatment of drug-induced liver injury.Methods:Totally seven Chinese and English databases,including CNKI,Wanfang,VIP,CBM,PubMed,EMbase,Web of Science were searched for randomized controlled trials(RCTs)of Hugan Tablets(护肝片)for the treatment of drug-induced liver injury,which were published from the date of establishment to April 20,2019.The meta-analysis software RevMan 5.3 software and Excel were used to build a database into combine and analyze the studies that met the standards and to draw a forest plot.Results:Forty five RCTs were included with 7478 patients.The quality of included studies was uneven.Meta-analysis showed that the outcome index of liver injury rate was divided into seven subgroups.Hugan Tablets(护肝片)were used in the treatment of anti-tuberculosis drugs was superior to the conventional western medicine treatment group(RR=0.27,95%CI[0.22,0.33],P<0.00001).Which was also better than the without Hugan Tablets(护肝片)treatment group(RR=0.32,95%CI[0.20,0.52],P<0.00001).For the role of drug-induced liver injury in the treatment of type 2 diabetes,the Hugan Tablet+conventional treatment group is better than the conventional treatment group(RR=0.16,95%CI[0.03,0.88],P=0.03).The effect of drug-induced liver injury in the treatment of hypertension was superior to the conventional western medicine treatment group(RR=0.07,95%CI[0.03,0.14],P<0.00001).The effect of drug-induced liver injury during the treatment of hyperlipidemia was not statistically significant(RR=0.57,95%CI[0.33,1.00],P=0.05).There was no statistical difference between the two groups in the effect of drug-induced liver injury during the treatment of coronary heart disease(RR=0.09,95%CI[0.01,1.61],P=0.10).There was no significant difference between the two groups in the treatment of cerebral thrombosis for drug-induced liver injury(RR=0.11,95%CI[0.01,2.01],P=0.14).The effect of anti-hyperthyroidism on liver injury was better than that of conventional western medicine treatment group(RR=0.45,95%CI[0.25,0.82],P=0.009).Outcome index of total effective rate was divided into two subgroups.The effect of drug-induced liver injury caused by the type of drug was not mentioned was superior to the conventional western medicine treatment group(RR=0.78,95%CI[0.70,0.88],P<0.0001).There was no significant difference between the two groups in the liver injury caused by antipsychotic drugs(RR=0.97,95%CI[0.81,1.16],P=0.72).Conclusion:When used in the treatment of tuberculosis and psychiatric drug treatment,combineduse of Hugan Tablets(护肝片)can significantly reduce the incidence of drug-induced liver damage,and can significantly improve clinical symptoms caused by liver damage.In the treatment of hypertension,the addition of Hugan Tablets(护肝片)can significantly reduce the incidence of drug-induced liver injury,improving the safety of medication.In the treatment of drug-induced liver injury caused by which drug is not mentioned,Hugan Tablet has a therapeutic effect.Slight adverse reactions were reported,including rash,headache,palpitations,hypoglycemia,flushing,fatigue,nausea,bowel sounds,flatulence,diarrhea,and gastrointestinal discomfort.All studies reported minor adverse reactions that were well tolerated by patients and recovered without treatment after discontinuation.Oral administration of Hugan Tablets(护肝片)has positive effects on druginduced liver injury,but this conclusion still needs further evidences delete.It is necessary to adopt a larger sample,more design,and accord with the international standards to improve the quality of evidence.
文摘To evaluate the effectiveness and safety of Jinye Baidu Granules(金叶败毒颗粒)for acute upper respiratory tract infection(AURTI).Database such as CNKI,Wan-fang,VIP,Sino Med,Web of science,Clinical Trials gov,Medline、EMBASE,CENTRAL,Cochrane Library were retrieved to collect randomized controlled trials(RCTs)on Jinye Baidu Granules(金叶败毒颗粒)in treating AURTI from the estabslishment of the database to March 2019.A total of 2 reviewers independently screened the literature according to the inclusion and exclusion criteria,and extracted material and the quality evaluation of the included studies.Quality evaluation adopted Cochrane Handbook 5.1 evaluation standards and tools.Rev Man5.3 was used to perform Meta-analysis for the adopted study.Finally a total of 4 RCTs involving 636 patients were included.Meta-analysis results showed that:compared with conventional Western medicine alone,Jinye Baidu Granules(金叶败毒颗粒)combined with Western medicine in the treatment of acute upper respiratory tract infection can improve the total effective rate of clinical efficacy[RR=0.13,95%CI(0.06,0.29),P<0.00001],shorten the time of antipyretic time for acute upper respiratory tract infection[MD=–1.22,95%CI(–1.43,–1.00),P<0.00001],shorten the time of pharyngeal pain[MD=–1.97,95%CI(–2.97,–0.96),P<0.0001]and shorten the cough disappear time[MD=–1.97,95%CI(–2.97,–0.96),P<0.0001].There were 2 papers reporting adverse reactions during the study period,and one of them specifically reported diarrhea,nausea,vomiting and stomachache in the experimental group.In the control group:diarrhea,nausea and adverse reactions disappeared after drug withdrawal;the incidence of adverse reactions was 3.92%in the control group and 5.88%in the observation group.There was no significant difference between the 2 groups(P>0.05).Based on existing data and methods,the systematic evaluation showed that,compared with Western medicine alone,Jinye Baidu Granules(金叶败毒颗粒)combined with Western medicine alone could improve the total effective rate of clinical efficacy,reduce the time of fever,sore throat,and the disappearance of cough with less adverse reactions.However,due to the low quality of the included study,large samples,multicenter,randomized,double-blind trials and trials are still needed to randomized controlled trials with reference to the CONSORT standard and the STRICTA statement.
基金National Key Research&Development Plan Project(2018YFC1707400,2018YFC1707410)Research Funding Project For Graduate Education Teaching Reform of China Academy of Chinese Medical Sciences(JG201703)
文摘To systematically evaluate the efficacy and safety of Pudilan Xiaoyan Oral in Liquid(蒲地蓝消炎口服液)in the treatment of suppurative tonsillitis in children.In WanFang,CNKI,VIP,CBM,PubMed,Embase and Corchrane and other databases,relevant literatures about Pudilan Xiaoyan Oral Liquid(蒲地蓝消炎口服液)in the treatment of pediatric suppurative tonsillitis were searched.The retrieval time was from the establishment of the database to April 2019.Relevant randomized controlled trials were extracted.The control group was treated with conventional antibiotics,and the observation group was treated with Pudilan Xiaoyan Oral Liquid(蒲地蓝消炎口服液)based on the control group.After they were summarized and analyzed,Cochrane Handbook 5.1 evaluation standard and RevMan 5.3 software were used to determine the quality of literature.A total of 172 literatures were retrieved and 23 randomized controlled trials were included.A total of 1188 children were in the experimental group while 1175 children were in the control group,involving 2363 children with suppurative tonsillitis.Meta-analysis showed that the total effective rate of Pudilan Xiaoyan Oral Liquid(蒲地蓝消炎口服液)combined with routine treatment was better than that of routine treatment(RR=0.88,95%CI(0.86,0.91),P<0.00001);Pudilan Xiaoyan Oral Liquid(蒲地蓝消炎口服液)combined with routine treatment in children was better than that of routine treatment alone in term of temperature recovery,sore throat time,the reduction of tonsil purulent secretion.There were few reports of adverse reactions and no serious adverse reactions.To sum up,Pudilan Xiaoyan Oral Liquid(蒲地蓝消炎口服液)combined with routine treatment can significantly improve the efficacy of children with suppurative tonsillitis,but due to the low quality of the included literature,it should be used cautiously.It is suggested that clinical randomized controlled trials should be designed with large sample size,multi-centers and conforming to international standards to improve the quality of evidence.
基金National Key Research and Development Plan Project(2018YFC1707400)Basic Business Expense Project of Central Public Welfare Research Institutes(Z0605)。
文摘Objective:To systematically evaluate the efficacy and safety of Fuke Qianjin Tablets(妇科千金片)in the treatment of chronic pelvic inflammation.Methods:A systematically and comprehensively search was conducted in 4 Chinese databases of CNKI,VIP,Wan Fang and CBM and the foreign language databases of Pubmed,EMbase and The Cochrane Library.The retrieval time was from database establishment to March 2019.The randomized controlled trials of Fuke Qianjin Tablets(妇科千金片)in the treatment of chronic pelvic inflammation were selected according to the predetermined criteria.The quality of the included study was evaluated by Cochrane collaborative network bias risk evaluation tool,and the meta-analysis was performed by Rev Man5.3 software.Results:A total of 1009 related literatures were searched.After initial screening and strict evaluation,55 studies were included,with a total sample size of 6826 cases,including 3416 cases in the experiment group and 3410 cases in the control group.The results of meta-analysis showed that the total effective rate of Fuke Qianjin Tablets(妇科千金片)combined with antibiotics in the treatment of chronic pelvic inflammation was better than that of antibiotics alone(RR=1.20,95%CI[1.17,1.22],P<0.00001).Fuke Qianjin Tablets(妇科千金片)combined with antibiotics was better than that of antibiotics alone in the improvement of abdominal pain symptoms(RR=1.40,95%CI[1.04,1.88],P<0.00001),leukorrhea abnormality(RR=1.38,95%CI[1.16,1.65],P<0.0004).In terms of safety,Fuke Qianjin Tablets(妇科千金片)combined with antibiotics could reduce the incidence of adverse reactions(RR=0.67,95%CI[0.48,0.93],P<0.02).The main adverse reactions were nausea and vomiting,bitterness and astringency in the mouth,rash and so on.All of them could be tolerated and the symptoms could disappear in the short term,and had no effect on the treatment.Conclusion:Fuke Qianjin Tablets(妇科千金片)combined with antibiotics in the treatment of chronic pelvic inflammation can improve the total effective rate,relieve abdominal pain and abnormal leukorrhea and other clinical discomfort symptoms,improve the quality of life of patients to a certain extent,and no serious adverse reactions are found.Due to the limitation of the quality and quantity of the included literature,the above conclusions need to be further studied and verified by high-quality research.
基金China Academy of Chinese Medical Sciences Project approval:Science and technology innovation project of China Academy of Chinese Medical Sciences(ci2021a00702)approval:National key R&D plan"demonstration study on evidence-based evaluation and effect mechanism of ten large varieties of Chinese patent medicines and classic famous prescriptions in the treatment of major diseases after listing(2018yfc1707400)。
文摘Objective:To explore the efficacy of Lianhua Qingwen Capsule(莲花清瘟胶囊)on upper respiratory tract infection,to understand the impact of Lianhua Qingwen Capsule(莲花清瘟胶囊)on the treatment outcome of upper respiratory tract infection,and provide reference for rational clinical drug use.Methods:The HIS database based on 18 large third-grade class-A hospitals was selected to match 1:1 for upper respiratory tract infection patients using and without Lianhua Qingwen Capsule(莲花清瘟胶囊)according to certain standards.The recombination of treatment outcome as"recovery"and"improvement"in the database was defined as effective treatment,"ineffectiveness","death"and"other"as ineffectivetreatment populations,and the effectiveness of treatment outcomes in the remerged 2 groups was compared by propensity score method.Results:After matching,454 cases were in both the patients treated by(experimental group)and without(control group)Lianhua Qingwen Capsule(莲花清瘟胶囊).Analysis was performed by three Logistic regression methods,all showing regression coefficients greater than 0 and statistically significant differences(P<0.05).Conclusion:Patients with upper respiratory tract infection treated by Lianhua Qingwen Capsule(莲花清瘟胶囊)are more effective than that without Lianhua Qingwen Capsule(莲花清瘟胶囊),it can improve the clinical efficacy of patients with upper respiratory tract infection。
基金Supported by National Key Research&Development Plan(2018YFC1707400,2018YFC1707410)。
文摘To systematically evaluate the clinical efficacy and safety of Maren Runchang Pill(麻仁润肠丸)in the treatment of senile constipation.Randomized controlled trials(RCT)on the treatment of senile constipation with Maren Runchang Pill(麻仁润肠丸)were searched by computer in CNKI,CBM,WanFang,VIP,PubMed,EMbase and the Cochrane Library databases.The retrieval time limit was from the establishment of the database to May 2019.A total of 2 researchers independently screened literature and extracted data according to the inclusion criteria,and Meta-analyzed the RCT that met the standards by applying RevMan5.3 software.A total of 5 randomized controlled trials were included,including 395 patients with senile constipation,199 in the experimental group and 196 in the control group.The treatment group was treated with Maren Runchang Pill(麻仁润肠丸),while the control group was treated with other Western medicine,including fruit guide tablets,lactulose oral liquid or kaisailu,etc.The results of Meta-analysis showed that there was no significant difference in the total clinical efficacy between Maren Runchang Pill(麻仁润肠丸)and other Western medicines[RR=1.02,95%CI(0.88,1.17),P=0.83].In terms of improvement of abdominal distension and inappetence,there was no significant difference between the treatment with Maren Runchang Pill(麻仁润肠丸)and other Western medicine[RR=1.03,95%CI(0.85,1.24),P=0.78].Maren Runchang Pill(麻仁润肠丸).This study showed that the efficacy of Maren Runchang Pill(麻仁润肠丸)in the treatment of senile constipation was not significantly different from that of conventional Western medicine,and was safe,and effective,with few adverse reactions.Maren Runchang Pill(麻仁润肠丸),as a traditional Chinese patent medicine,can play the role of regulating qi and replenishing blood,and regulating bowel and bowel laxative,with fewer cost.It is more suitable for the elderly to use,with good compliance,and clinically it should be used with syndrome differentiation.However,due to the quantity and quality of the original study,multi-center,high-quality randomized controlled trials are still needed to further confirm it.
文摘系统评价热毒宁注射液治疗急性气管-支气管炎的有效性和安全性。计算机检索中国知网、万方、维普、Sino Med、Cochrane Library、Medline、Web of Science从建库至2019年4月发表的期刊文献、学术论文及会议论文,收集热毒宁注射液治疗急性气管-支气管炎的随机对照试验(RCTs)。由2名研究者独立进行文献筛选、数据提取及偏倚风险评估,采用Rev Man 5.3进行Meta分析。最终纳入14篇随机对照试验文献,涉及1652例患者。Meta分析结果显示:在临床总有效率方面,热毒宁注射液优于利巴韦林治疗(RR=1.37,95%CI[1.28,1.47],P<0.00001);热毒宁注射液联合常规治疗优于常规治疗(RR=1.14,95%CI[1.09,1.19],P<0.00001);热毒宁注射液联合阿奇霉素治疗优于阿奇霉素治疗(RR=1.21,95%CI[1.07,1.37],P=0.002)。在临床症状方面,热毒宁注射液治疗的平均退热时间短于利巴韦林治疗(MD=-1.68,95%CI[-1.72,-1.49],P<0.00001);咳嗽消失时间短于利巴韦林治疗(MD=-2.57,95%CI[-2.91,-2.24],P<0.00001);肺部啰音消失时间短于利巴韦林治疗(MD=-2.26,95%CI[-2.71,-1.80],P<0.00001);热毒宁注射液联合常规治疗肺部啰音消失时间短于单用常规治疗(MD=-1.77,95%CI[-1.95,-1.59],P<0.00001)。基于此研究结果,热毒宁注射液治疗可提高临床总有效率,缩短平均退热时间、咳嗽与肺部啰音消失时间,不良反应轻微且发生率低。但鉴于纳入研究质量不高,需采用大样本、设计严谨、符合国际规范的临床试验方案以提高证据质量级别。
